OZOCLO_MUCOSITIS: a New Protocol for Prevention of Oral Mucositis (OZOCLO_MUCOS)

OZOCLO: a Randomized Clinical Trial for Prevention of Oral Mucositis

Oral mucositis (OM) is a significant side effect of cytotoxic anti-cancer chemotherapy and HN radiotherapy. CT-associated OM (CT-OM). It is the ulcerative phase that is most painful and associated with poor health outcomes. The sequelae of CT-OM, which include pain, odyno/dys-phagia, dysgeusia, decreased oral intake and systemic infection, frequently require treatment delays, interruptions, and discontinuations that not only negatively impact the quality of life but also tumor control and survivorship. To date, OM management is aimed to control symptoms through topical or systemic analgesics and topical application of barrier agents to cover injured mucosa as a salve or ointment. According to the recent MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy, no guideline was possible regarding the use of saline or sodium bicarbonate rinses in the prevention or treatment of OM-CT in patients undergoing cancer therapy because of limited data.

Ozone at low medical concentration, not included in MASCC guidelines, will be generally proven to induce a mild activation of protective anti-oxidant pathways, thus exerting therapeutic effects in many inflammatory diseases.

Aim: to evaluate the effectiveness of a new protocol OZOCLO (alpha-lipoic acid, ozonated oil, and chlorhexidine [CHX] mouthwash) compared to sodium bicarbonate solution (Oral Basic Care- OBC) or chlorhexidine (CHX) mouthwash alone or to a binomial administration (AAL-OZ) of systemic alpha-lipoic acid and topical ozonated oil to reduce the incidence of OM (primary aim) and/or to postpone the beginning of oral mucositis (OM) and to reduce OM severity (secondary aims).

Study Overview

• Status: Not yet recruiting
• Conditions: Mucositis (MeSH Unique ID: D052016); Stomatitis (MeSH Unique ID: D013280)
• Intervention / Treatment: Drug: 1. alpha acid lipoic - tables; Drug: 2. ozonated oil - mouthwash; Drug: 3. chlorhexidine 0,2% - mouthwash; Drug: 4. sodium bicarbonate 5% solution - mouthwash

Detailed Description

Oral mucositis (OM) is a significant side effect of cytotoxic anti-cancer chemotherapy and HN radiotherapy. CT-associated OM (CT-OM) begins in the submucosa and becomes clinically on the surface about 4 days after infusion: typical primary manifestations are erythema, mucosal atrophy, and sensitivity. The process continues to deteriorate mucosae, and ulceration occurs a few days later, peaking at 2 weeks and persisting for 1-2 weeks after which it typically resolves spontaneously. It is the ulcerative phase that is most painful and associated with poor health outcomes. The sequelae of CT-OM, which include pain, odyno/dys-phagia, dysgeusia, decreased oral intake and systemic infection, frequently require treatment delays, interruptions, and discontinuations that not only negatively impact the quality of life but also tumor control and survivorship. To date, OM management is aimed to control symptoms through topical or systemic analgesics and topical application of barrier agents to cover injured mucosa as a salve or ointment. Although the investigators reviewed a large body of evidence, there are still, clinical settings for which there is no recommended intervention. According to the recent MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy, no guideline was possible regarding the use of saline or sodium bicarbonate rinses in the prevention or treatment of OM-CT in patients undergoing cancer therapy because of limited data. Despite the limited data available for both saline and sodium bicarbonate, the panel recognizes that these are inert, bland rinses that increase oral clearance, which may help maintain oral hygiene and improve patient comfort. Also, CHX is indicated because of concurrent oral infection and OM, it is acceptable to use it for the oral infection.

Ozone at low medical concentration, not included in MASCC guidelines, will be generally proven to induce a mild activation of protective anti-oxidant pathways, thus exerting therapeutic effects in many inflammatory diseases.

Aim: to evaluate the effectiveness of a new protocol OZOCLO (alpha-lipoic acid, ozonated oil, and chlorhexidine [CHX] mouthwash) compared to sodium bicarbonate solution (Oral Basic Care- OBC) or chlorhexidine (CHX) mouthwash alone or to a binomial administration (AAL-OZ) of systemic alpha-lipoic acid and topical ozonated oil to reduce the incidence of OM (primary aim) and/or to postpone the beginning of oral mucositis (OM) and to reduce OM severity (secondary aims).

• Study Type: Interventional
• Enrollment (Anticipated): 80
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Olga Di Fede, Professor; Phone Number: +39 3294030298; Email: olga.difede@unipa.it

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Aged 18-80 years

• Planned to receive conventional chemotherapy such as:

  • CMF (cyclophosphamide (Endoxan), methotrexate, 5-FU))
  • Standard AC+T regimen (doxorubicin (Adriamycin)), cyclophosphamide (Endoxan), Taxane [paclitaxel (Taxol) or docetaxel (Taxotere)) or any combination of two or more components (e.g., ACT, TAC, TA, AT, AC)
  • ABVD (doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine)
  • FOLFIRI (irinotecan, 5-FU, leucovorin)
  • Any other 5-FU-based regimen
• Planned to receive at conventional new generation targeted agents (tyrosine-kinase inhibitors or monoclonal antibodies) such as cetuximab, axitinib, bevacizumab, sunitinib, and sorafenib, temsirolimus, everolimus, vemurafenib, dabrafenib.
• Be willing and able to complete all study-related activities
• Properly obtained written informed consent

Exclusion Criteria:

• Receiving any oxaliplatin-containing chemotherapy regimen, such as FOLFOX
• Concurrent radiotherapy
• Unable or unwilling to complete study assessments
• Concurrent participation in another interventional clinical study or use of another investigational agent within 30 days before randomization
• Any other clinical or psychiatric condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the protocol
• Chronic use of opioid analgesics

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group I, OZOCLO; • Group I, OZOCLO; alpha acid lipoic - 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days; ozonated oil - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 2 weeks; chlorhexidine 0,2% - mouthwash (1 minute- three times/die after oral hygiene, possibly) from five days after the beginning of chemotherapy and for subsequent 2 weeks	Drug: 1. alpha acid lipoic - tables; 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days; Other Names: alpha acid lipoic - tables; Drug: 2. ozonated oil - mouthwash; 1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 2 weeks; Other Names: ozonated oil - mouthwash; Drug: 3. chlorhexidine 0,2% - mouthwash; 1 minute- three times/die after oral hygiene, possibly, from five days after the beginning of chemotherapy and for subsequent 2 weeks; Other Names: chlorhexidine 0,2% - mouthwash
Placebo Comparator: Group II, OBC; • Group II, OBC Sodium bicarbonate 5% solution - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 3 weeks	Drug: 4. sodium bicarbonate 5% solution - mouthwash; 1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 3 weeks; Other Names: sodium bicarbonate 5% solution - mouthwash
Active Comparator: Group III, CHX; • Group III, CHX Chlorhexidine 0,2% - mouthwash (1 minute- three times/die after oral hygiene, possibly) from five days after the beginning of chemotherapy and for subsequent 2 weeks	Drug: 3. chlorhexidine 0,2% - mouthwash; 1 minute- three times/die after oral hygiene, possibly, from five days after the beginning of chemotherapy and for subsequent 2 weeks; Other Names: chlorhexidine 0,2% - mouthwash
Active Comparator: Group IV, AAL-OZ; • Group IV, AAL-OZ; alpha acid lipoic - 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days; ozonated oil - mouthwash (1 minute- three times/die after oral hygiene, possibly) from the beginning of chemotherapy and for 2 weeks	Drug: 1. alpha acid lipoic - tables; 600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days; Other Names: alpha acid lipoic - tables; Drug: 2. ozonated oil - mouthwash; 1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 2 weeks; Other Names: ozonated oil - mouthwash

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of OM incidence	In order to demonstrate whether the new protocol OZOCLO determines change of the incidence of OM compared to sodium bicarbonate solution (OBC) or chlorhexidine (CHX) mouthwash alone or the binomial AAL-OZ combination, in patients treated with chemotherapy regimens.	7th, 14th, and the 21st day after application of the interventions

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Delay onset of OM	In order to determine whether the new protocol OZOCLO determines a delay of onset for OM, considering that it currently begins at 7th day, compared to sodium bicarbonate solution (OBC) or chlorhexidine (CHX) mouthwash alone or a binomial administration of systemic alpha-lipoic acid and topical ozonated oil.	7th, 14th, and the 21st day after application of the interventions

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
OM severity assessment	To reduce OM severity, assuming one-point score difference (assessed through the Oral Mucositis World Health Organization Toxicity Scale- from grade 0 - none to grade IV- Oral alimentation impossible) compared to chlorhexidine (CHX) mouthwash alone or a binomial administration of systemic alpha-lipoic acid and topical ozonated oil and two-point score difference compared to sodium bicarbonate solution at one year.	7th, 14th, and the 21st day after application of the interventions

Collaborators and Investigators

• Sponsor: University of Palermo
• Investigators: Principal Investigator: Olga Di Fede, Professor, University of Palermo, Di.Chir.On.S

Publications and helpful links

General Publications

• Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020 Oct 1;126(19):4423-4431. doi: 10.1002/cncr.33100. Epub 2020 Jul 28. Erratum In: Cancer. 2021 Oct 1;127(19):3700.
• Cardona A, Balouch A, Abdul MM, Sedghizadeh PP, Enciso R. Efficacy of chlorhexidine for the prevention and treatment of oral mucositis in cancer patients: a systematic review with meta-analyses. J Oral Pathol Med. 2017 Oct;46(9):680-688. doi: 10.1111/jop.12549. Epub 2017 Feb 8.
• Ferretti GA, Raybould TP, Brown AT, Macdonald JS, Greenwood M, Maruyama Y, Geil J, Lillich TT, Ash RC. Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial. Oral Surg Oral Med Oral Pathol. 1990 Mar;69(3):331-8. doi: 10.1016/0030-4220(90)90295-4.

Study record dates

Study Major Dates

• Study Start (Anticipated): March 10, 2022
• Primary Completion (Anticipated): December 31, 2022
• Study Completion (Anticipated): January 10, 2023

Study Registration Dates

• First Submitted: December 14, 2021
• First Submitted That Met QC Criteria: January 26, 2022
• First Posted (Actual): January 27, 2022

Study Record Updates

• Last Update Posted (Actual): January 27, 2022
• Last Update Submitted That Met QC Criteria: January 26, 2022
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Gastroenteritis; Stomatognathic Diseases; Mouth Diseases; Mucositis; Stomatitis; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents, Local; Anti-Infective Agents; Protective Agents; Dermatologic Agents; Micronutrients; Vitamins; Antioxidants; Vitamin B Complex; Disinfectants; Pharmaceutical Solutions; Chlorhexidine; Thioctic Acid; Chlorhexidine gluconate
• Other Study ID Numbers: OZOCLO_MUCOSITIS 01_2021

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No